- Home
- SILO vs CMND Comparison
SILO vs CMND Comparison
Compare SILO & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILO | CMND |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 2.2M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SILO | CMND |
|---|---|---|
| Price | $0.33 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 408.8K | 107.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.83 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $72,102.00 | N/A |
| Revenue This Year | $1.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.07 |
| 52 Week High | $1.44 | $3.25 |
Technical Indicators
Market Signals| Indicator | SILO | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 47.76 | 34.57 |
| Support Level | $0.33 | $0.93 |
| Resistance Level | $0.45 | $1.27 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 66.98 | 14.29 |
Price Performance
Historical ComparisonAbout SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.